CLSA Premium Ltd. (HK:6877) has released an update.
CLSA Premium Limited has announced the successful fulfillment of the resumption guidance set by the Stock Exchange, resulting in a notable turnaround for its Healthcare Business. The company’s diligent management has led to a significant revenue increase to HK$191.4 million and a net profit of HK$9.8 million in 2023, showcasing its potential for growth and marking a stark improvement from the previous year’s net loss.
For further insights into HK:6877 stock, check out TipRanks’ Stock Analysis page.
